Late diagnosis of hepatitis B and C remains common and is driven by factors like older age, male sex, comorbidities, and ...

Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.

Patty Taddei-Allen, PharmD, MBA, examines how co-pay accumulators, maximizers, and AFPs shift costs, impact rebates, and ...

At AMCP 2026, Adam Colborn, JD, warns the Alternatives to PAIN Act may expand access but risk destabilizing Medicare Part D and limiting plan participation. The Academy of Managed Care Pharmacy (AMCP) ...

Inconsistent use and wording of the “Not Better Explained” diagnostic criterion across major sleep disorder classifications ...

Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity ...

Oncology care is constantly evolving, and it’s important for clinicians and pharmacists alike to stay up-to-date on various ...

The Greater Philadelphia Business Coalition on Health will anchor a NACDD-selected 2026 regional summit to expand employer ...

Ultimate disposition showed 54% approval (7% same-day; 47% after multiple days) and 46% denial, with 27% rejected within 1 ...

World Hemophilia Day spotlights the rare blood disorder that prevents the blood from clotting and can be dangerous when left ...

High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance design should eliminate patient cost sharing for these therapies. 259 Prospect ...